Clovis’ PARP inhibitor Rubraca under EU review in maintenance setting
European regulators have agreed to review Clovis’ application to expand the use of its PARP inhibitor Rubraca in the region.
Read More
Tag: ARIEL3
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
